![\"\"](\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Logo20icrowd.png\")
<\/p>\n<\/p>\n
DelveInsight’s <\/span>End-Stage Renal Disease (ESRD) Market Insights Report<\/strong><\/a> offers a detailed analysis of Disease, its causes, symptoms, diagnostics modalities, and treatment options. <\/span><\/p>\n End-Stage Renal Disease (ESRD) market size and share, epidemiology, new treatments, market drivers and barriers, ongoing clinical trials, critical partnership in the space, and critical pharmaceutical companies actively moving the End-Stage Renal Disease market size forward are all covered in depth in this study.<\/span><\/p>\n Some of the key highlights from the<\/strong> End-Stage Renal Disease (ESRD) Market<\/strong><\/a> Insights: <\/strong><\/p>\n Learn more by requesting for sample @ <\/span>End-Stage Renal Disease (ESRD) Market Landscape<\/strong><\/a><\/p>\n ESRD: Overview<\/strong><\/p>\n The final stage of chronic kidney disease is end-stage renal disease (ESRD), also known as kidney failure. Even though there is no treatment for ESRD, many people on dialysis (hemodialysis or peritoneal dialysis) or who have had a kidney transplant live long lives.<\/span><\/p>\n According to the National Kidney Foundation, over 17,000 kidney transplants were completed in the United States in 2014.<\/span><\/p>\n To help avoid Renal failure, people with diabetes or hypertension should keep their conditions under control. Angiotensin-converting enzyme inhibitors (ACE inhibitors\/ACEi) or angiotensin receptor blockers are used to treat both conditions (ARBs).<\/span><\/p>\n ACEi\/ARB therapy not only reduces proteinuria (and albuminuria) but decreases the yearly number of diabetic patients going on to require dialysis. Reduced hyper-filtration is consistent with the clinical observation. The introduction of ACEi\/ARB therapy is associated with an acute decrease in estimated glomerular filtration rate (eGFR) and the fact that more significant eGFR reductions were associated with less long-term loss of renal function. Although ACEi\/ARB therapy slows renal functional failure in DN, it by no means induces remission or even halts progression to ESRD.<\/span><\/p>\n For more insights into Disease, causes, and treatment, reach out @ <\/span>End-Stage Renal Disease (ESRD) Treatment Landscape<\/strong><\/a>.<\/span><\/p>\n End-Stage Renal Disease (ESRD) Epidemiology Segmentation <\/strong><\/p>\n The <\/span>End-Stage Renal Disease (ESRD) Market<\/strong> report proffers epidemiological analysis for the study period 2017-30 in the 7MM segmented into:<\/span><\/p>\n Visit for more @<\/span> End-Stage Renal Disease (ESRD) Epidemiological Insights<\/strong><\/a>.<\/strong><\/p>\n End-Stage Renal Disease Market<\/strong><\/p>\n With the launch of emerging therapies, key companies operating in the space, increasing prevalence, increased R&D in the field, and medical advances in the End-Stage Renal Disease (ESRD) market domain, the End-Stage Renal Disease (ESRD) market size is expected to grow.<\/span><\/p>\n End-Stage Renal Disease (ESRD) Key Companies<\/strong> and Pipeline Therapies<\/strong><\/span><\/p>\n For more information, visit <\/span>End-Stage Renal Disease (ESRD) Market Analysis, Patient Pool, and Emerging Therapies<\/strong><\/a>.<\/span><\/p>\n End-Stage Renal Disease (ESRD) Market Drivers<\/strong> <\/span><\/p>\n <\/p>\n Scope of the Report<\/strong><\/p>\n <\/p>\n Key Questions Answered in the Report<\/strong><\/p>\n Get in touch with our Business executive @ <\/span>End-Stage Renal Disease (ESRD) Market<\/strong><\/a> Landscape Analysis<\/strong>. <\/span><\/p>\n Table of Contents <\/strong><\/p>\n Learn more about the report offerings @ <\/strong>End-Stage Renal Disease (ESRD) Market Outlook<\/strong><\/a><\/p>\n Related Reports<\/strong>:<\/span><\/p>\n End-Stage Renal Disease (ESRD) Pipeline<\/strong><\/a><\/p>\n Get comprehensive historical and forecast analysis of End-Stage Renal Disease Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as <\/span>Rockwell Medical Technologies<\/strong>, <\/span>Aronora<\/strong>, <\/span>Dynavax Technologies Corporation<\/strong>, <\/span>Merck,<\/strong> and several others.<\/strong><\/p>\n![\"End-Stage](\"http:\/\/beta-kiosk.icrowdnewswire.com\/assets\/source\/users\/delveinsight\/End-Stage%20Renal%20Disease%20(ESRD)%20Market%20Insights.jpg?1620040337304\")
<\/span><\/p>\n\n
\n
\n
\n
\n
\n
\n\n
\n 1.<\/td>\n Key Insights <\/span><\/td>\n<\/tr>\n \n 2.<\/td>\n Report Introduction<\/span><\/td>\n<\/tr>\n \n 3.<\/td>\n End-Stage Renal Disease Competitive Intelligence Analysis (ESRD)<\/span><\/td>\n<\/tr>\n \n 4.<\/td>\n End-Stage Renal Disease (ESRD) Market Overview at a Glance<\/span><\/td>\n<\/tr>\n \n 5.<\/td>\n Executive Summary of End-Stage Renal Disease (ESRD)<\/span><\/td>\n<\/tr>\n \n 6.<\/td>\n End-Stage Renal Disease (ESRD) Epidemiology and Market Methodology<\/span><\/td>\n<\/tr>\n \n 7.<\/td>\n End-Stage Renal Disease (ESRD) Epidemiology and Patient Population<\/span><\/td>\n<\/tr>\n \n 8.<\/td>\n End-Stage Renal Disease (ESRD) Patient Journey<\/span><\/td>\n<\/tr>\n \n 9.<\/td>\n Treatment Algorithm, Current Treatment, and Medical Practices<\/span><\/td>\n<\/tr>\n \n 10.<\/td>\n Critical Endpoints in End-Stage Renal Disease (ESRD) Clinical Trials<\/span><\/td>\n<\/tr>\n \n 11.<\/td>\n End-Stage Renal Disease (ESRD) Marketed Therapies <\/span><\/td>\n<\/tr>\n \n 12.<\/td>\n End-Stage Renal Disease (ESRD) Emerging Therapies<\/span><\/td>\n<\/tr>\n \n 13.<\/td>\n End-Stage Renal Disease (ESRD): 7 Major Market Analysis<\/span><\/td>\n<\/tr>\n \n 14.<\/td>\n Attribute analysis<\/span><\/td>\n<\/tr>\n \n 15.<\/td>\n Access and Reimbursement Overview of End-Stage Renal Disease (ESRD)<\/span><\/td>\n<\/tr>\n \n 16. <\/td>\n KOL Reviews<\/span><\/td>\n<\/tr>\n \n 17.<\/td>\n Case Reports<\/span><\/td>\n<\/tr>\n \n 18.<\/td>\n End-Stage Renal Disease (ESRD) Market Drivers<\/span><\/td>\n<\/tr>\n \n 19.<\/td>\n End-Stage Renal Disease (ESRD) Market Barriers<\/span>
<\/span><\/td>\n<\/tr>\n\n 20.<\/td>\n SWOT Analysis<\/span><\/td>\n<\/tr>\n \n 21.<\/td>\n Disclaimer<\/span><\/td>\n<\/tr>\n \n 22.<\/td>\n DelveInsight Capabilities<\/span>
<\/span><\/td>\n<\/tr>\n\n 23.<\/td>\n About DelveInsight<\/span>
<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n